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Dear Member of the Media: 
Tr a d i t i o n a l l y , patients with an early stage of the most malignant form of 
te s t i c u l a r cancer underwent two major surgeries--one to remove the testes and 
another to clear the lymph nodes. Now, the majority need only endure removal 
of the testes, eliminating the potential complications of a second major 
surgery. The current state of treatment f o r t e s t i c u l a r cancer i s summarized 
by two University Hospital(UH) physicians i n the July issue of Urology. 
Testicular cancer i s one of the most common cancers i n men aged 15 to 34. 
Nonseminomatous cancer, the most common subtype, has been the hardest to t r e a t . 
Today, 80 percent of men who develop t h i s cancer can be cured compared with 
only 10 percent IS years ago. Now the focus of research i s to refine the 
treatment and minimize i t s side effects. 
Changes i n treatments are the result of prognostic-model research. 
Prognostic models are models of symptoms, laboratory studies, related factors 
and treatments--developed through retrospective studies--that can help predict 
the effectiveness of a treatment at each stage of a disease. 
"The goal of t h i s prognostic-model research i s to refine treatment 
decisions to select the most appropriate treatment f o r individual patients," 
says Paul Hesketh, M.D., a UH medical oncologist and an author of the a r t i c l e . 
Another important treatment modification made possible by prognostic 
models involves the management of late stage cancers that were t r a d i t i o n a l l y 
treated by removing the testes and administering chemotherapy, which was often 
toxic to other organs i n the body. Physicians can now distinguish between 
low-risk and high-risk cancers and can, therefore, j u s t i f y giving intensive 
chemotherapy to one patient and not to another. 
I f you would l i k e to interview Dr. Hesketh, please give me a c a l l at 
(617) 638-8491. 
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